Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

AdvaMed Steps Up Effort To Link Device Tax Repeal To Job Growth

This article was originally published in The Gray Sheet

Executive Summary

Device lobbyists are hoping to take advantage of renewed emphasis among federal policymakers on creating jobs to push through a repeal of the medical device excise tax, scheduled to take effect in 2013.

You may also be interested in...



The Medical Device Industry Stays The Course In 2012

The prospective medical device tax, the continuing decline of venture investing, pricing challenges, austerity measures in Europe, and other headwinds continued to push against the medtech industry in 2012. But emerging clinical and geographic markets, along with an active M&A market, provided the industry with some momentum.

Device Industry Amps Up Efforts To Repeal Device Tax In Lame Duck Session

Industry groups flew in more than 50 CEOs to visit Capitol Hill, launched an ad campaign and released an impact report last week as part of a stepped-up effort to get Congress to repeal the impending medical device tax before it goes into effect Jan. 1.

House Device Tax Repeal Effort May Raise Profile Of Issue In Election Season

Legislation to repeal the impending medical device excise tax will be sent to a vote on the House floor, raising the profile of the tax as a congressional election issue even as major impediments to repeal remain in the Senate. Meanwhile, the Supreme Court health care reform ruling looms.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT030514

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel